Prostate cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Prostate cancer is a type of cancer that appears in the prostate. Seminal fluid, which feeds and carries sperm, is secreted by the prostate, a tiny walnut-shaped gland in males. In North America, one in seven men are expected to develop prostate cancer (PCa) at some point in their lives. Up to 70% of castrate-resistant, metastatic PCa as well as roughly 25% of the initial PCa at radical prostatectomy are affected when the PTEN gene is inactivated by deletion or mutation, which results in the loss of PTEN protein. Treatment options for prostate cancer are based on prognostic factors such as baseline PSA level, clinical TNM stage, and Gleason score as well as other factors like baseline urinary function, comorbidities, and age.

Description

The term prostate cancer refers to cancer that starts in the prostate. The seminal fluid, which feeds and carries sperm, is secreted by the prostate, a tiny walnut-shaped gland in males. One in seven men in North America are expected to develop prostate cancer (PCa) at some point in their lives. Up to 70% of castrate-resistant, metastatic PCa as well as roughly 25% of the initial PCa at radical prostatectomy are affected when the PTEN gene is inactivated by deletion or mutation, which results in the loss of PTEN protein. Treatment options for prostate cancer are based on prognostic variables such as baseline PSA level, clinical TNM stage, and Gleason score as well as other variables like baseline urinary function, comorbidities, and age.

Prostate cancer (Epidemiology)

One in seven men in North America are expected to develop prostate cancer (PCa) at some point in their lives. Up to 70% of castrate-resistant and metastatic PCa as well as roughly 25% of the initial PCa at radical prostatectomy are affected when the PTEN gene is inactivated by deletion or mutation. PTEN loss in PCa malignancies is connected to invasive clinical traits and an early biochemical recurrence after initial therapies. Recent studies suggest that PTEN may also play roles outside of the PI3K/AKT pathway that are lipid phosphatase-independent, such as those that modify the immune system and the tumor microenvironment (TME) to influence the progression of tumors. Prostate cancer incidence varies more than 50 times across the globe, with the highest rates occurring in North America, Australia, Northern and Central Europe, and Southeast Asia, as well as the lowest rates occurring in North Africa and Central and South Asia. The most prevalent type of non-skin cancer in men in the US is prostate cancer. The likelihood of developing prostate cancer rises with age, with one in six white men and one in five Black men receiving a lifetime prostate cancer diagnosis. 268,490 new cases of prostate cancer are expected to be diagnosed in 2022, according to the American Cancer Society. Men under 40 and men under 50 are the two age groups in which prostate cancer is least likely to be discovered. Between 1989 and 1992, there was a sharp rise in the incidence of prostate cancer in the United States, which may have been attributed to the increased use of PSA blood tests that allowed for earlier detection in men who were asymptomatic. The incidence of organ-confined disease has also grown at the time of diagnosis as a result of PSA testing and conventional digital rectal examination. Since 1992, infection rates have decreased significantly, from over 230 per 100,000 people to less than 110 per 100,000 people between 2013 and 2017. An analysis of the roughly 800,000 cases of prostate cancer diagnosed between 2004 and 2013 revealed that, despite the incidence of low-risk prostate cancer declining by 37% between 2007 and 2013, the incidence of metastatic prostate cancer rose during this time. This is an increase of 72% over 2004. The incidence of metastatic prostate cancer was higher in men aged 55 to 69 (92%) than in other age groups. Age affects the likelihood of developing prostate cancer, with 60% of men over 65 receiving a diagnosis. Men between the ages of 65 and 74 are most likely to develop prostate cancer, and 66 is the average age at diagnosis. The incidence of prostate cancer among men under the age of 17 has increased worldwide, including in the United States, according to the Surveillance, Epidemiology, and Emerging Results (SEER) Program and Health Indicators. IHME Global Burden of Disease (GBD) database. These younger patients frequently experience more advanced cancer and have lower survival rates than men in their middle and late years. Since 1990, the incidence of prostate cancer in men between the ages of 15 and 40 has steadily risen worldwide, increasing by 2% annually. In the US, this age group has a six-fold higher risk of receiving the diagnosis than older men. The most prevalent men worldwide are Black and Afro-Caribbean, then white, Hispanic, and then Asian men who still reside in their country of origin. In nations with a high socioeconomic index, prostate cancer incidence is most prevalent.

Prostate cancer -Current Market Size & Forecast Trends

The market for prostate cancer treatment is projected to grow significantly, with estimates indicating a value of approximately USD 8.53 billion in 2024, expected to reach around USD 12.03 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.9% during this period. The increasing prevalence of prostate cancer, particularly among the aging population, along with advancements in treatment options such as targeted therapies and immunotherapies, are key drivers of this growth. North America is anticipated to dominate the market due to its advanced healthcare infrastructure and ongoing clinical trials, while regions like Asia-Pacific are expected to exhibit faster growth rates. Overall, the prostate cancer market is well-positioned for substantial expansion through 2035 as awareness and treatment strategies continue to evolve.

Treatment options for prostate cancer are based on prognostic factors such as baseline PSA level, clinical TNM stage, and Gleason score as well as other factors like baseline urinary function, comorbidities, and age. Doctors are now better able to risk-stratify their patients and recommend treatments based on the prognosis of the cancer and the preferences of their patients thanks to developments in the diagnosis and treatment of prostate cancer. For men with stage, I and stage III prostate cancer, the recommended treatments are surveillance, prostatectomy, and radiation therapy. Docetaxel and steroid prednisone are typically used as the first chemotherapy medication. Cabazitaxel is typically the next chemotherapy drug to try if that doesn't work (or if it stops working), though there may be other treatment options. Men who receive docetaxel or cabazitaxel tend to live longer on average than those who receive older chemotherapy medications. It can lessen symptoms and slow the spread of cancer, enhancing quality of life. However, it is unlikely that chemotherapy will be able to cure prostate cancer. Other chemotherapy drugs being researched for prostate cancer include carboplatin, oxaliplatin, and cisplatin. There is a cancer vaccine called Sipuleucel-T (Provenge). This vaccine strengthens the immune system by aiding it in attacking prostate cancer cells, as opposed to conventional vaccines that increase the body's immune system to help prevent infections. This vaccine is used to treat advanced prostate cancer that has little to no symptoms and is no longer responding to hormone therapy. Using drugs to recognize cancer cells and target them while causing the least amount of harm to healthy cells, targeted therapy is one type of cancer treatment. The programs that set cancer cells apart from healthy, normal cells are targeted by these treatments. Although each type of targeted therapy operates differently, they all alter the way cancer cells proliferate, divide, heal, or communicate with neighboring cells. PARP (poly (ADP)-ribose polymerase) inhibitors include the drugs rucaparib (Rubraca) and olaparib (Lynparza). In one pathway to aid in the repair of damaged DNA in cells, PARP enzymes are frequently involved. Because the BRCA genes (BRCA1 and BRCA2) are naturally involved in a number of DNA repair pathways, mutations in these genes can prevent the pathway from working. Because these medications inhibit the PARP pathway, cancer cells with abnormal BRCA genes have a harder time repairing DNA damage, which frequently results in cell death. All high-risk stage IV and III patients can experience a permanent remission after having their androgens removed surgically or medically through castration. Flutamide and bicalutamide are examples of first-generation antiandrogens that can be useful in this situation. Castration resistance, which is caused by mutations in the androgen receptor gene, almost always develops in the fourth stage, and the prognosis is dismal.

Report Highlights

Prostate cancer - Current Market Trends

Prostate cancer - Current & Forecasted Cases across the G8 Countries

Prostate cancer - Market Opportunities and Sales Potential for Agents

Prostate cancer - Patient-based Market Forecast to 2035

Prostate cancer - Untapped Business Opportunities

Prostate cancer - Product Positioning Vis-a-vis Competitors' Products

Prostate cancer - KOLs Insight